Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, Solange, Zimmermann, Stefan, Adjei, Alex A.·2014·Cancer Treatment Reviews
DOI 10.1016/j.ctrv.2014.06.010

Cited by (163)

Items 101–163 of 163

  1. Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
    Xiaoyan Chang, Chenghao Wang, Linyou Zhang · 2025 · Drug Design Development and Therapy
  2. Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis
    Teppei Yamaguchi, Hideki Hayashi, Sumito Isogai, Masamichi Hayashi, Sakurako Uozu, Yasuhiro Gotô, Toru Nakanishi, Tadashi Sugiyama, Yoshinori Itoh, Kazuyoshi Imaizumi · 2015 · Cancer Treatment Communications
  3. Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites
    Ali S. Abdelhameed, Mohamed W. Attwa, Adnan A. Kadi · 2019 · Royal Society Open Science
  4. Concomitant Gastric Acid Suppressants on the Survival of Patients with Non‐Small‐Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta‐Analysis
    Jun Xia, Jiping Zhu, Lei Li, Shiqin Xu · 2022 · International Journal of Clinical Practice
  5. Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
    Chou‐Chin Lan, Po‐Chun Hsieh, Chun-Yao Huang, Mei-Chen Yang, Wen‐Lin Su, Chih‐Wei Wu, Yao‐Kuang Wu · 2022 · World Journal of Clinical Cases
  6. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I
    Ying Wang, Xiang Nan, Yanping Duan, Qiuxu Wang, Zhigang Liang, Hanrong Yin · 2024 · Bioorganic & Medicinal Chemistry
  7. PCR-sequencing is a complementary method to amplification refractory mutation system for EGFR gene mutation analysis in FFPE samples
    Junchang Jiang, Chun‐Hua Wang, Xiaoli Yu, Danli Sheng, Zuo Chen, Minpu Ren, Yaqin Wu, Jie Shen, Mei Jin, Songxiao Xu · 2015 · Experimental and Molecular Pathology
  8. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation
    Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, Michelle M. Kuttel · 2019 · Biochemistry
  9. Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study
    Hui‐Hsia Hsieh, Tien‐Yuan Wu, Chi‐Hua Chen, Yu‐Hung Kuo, Mann‐Jen Hour · 2023 · BMC Cancer
  10. Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
    Giuseppe Lamberti, Elisa Andrini, Biagio Ricciuti · 2019 · Journal of Thoracic Disease
  11. Targeted therapies for lung cancer: how did the game begin?
    Nikolaos I. Kanellakis, Tiago Jacinto, Ioannis Psallidas · 2016 · Breathe
  12. Pharmacophore-guided review of EGFR-targeted anticancer drugs with gefitinib as a reference
    Meenu, Khursheed Ahmad Sheikh, Mohammad Shaquiquzzaman, Shivam Gupta, Barkha, Sharba Tasneem, Mymoona Akhter, Tarique Anwer, Mohammad Kaleem, Shalini Singh et al. · 2025 · European Journal of Medicinal Chemistry
  13. A Novel and Efficient Synthesis of Anti-Cancer Agent, Mereletinib
    Haidong Liu, Yong-Feng Lv, Yuan Li, Jin Cai, Junqing Chen, Qin Yu, Min Ji · 2015 · Journal of Chemical Research
  14. Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer
    Shan Li, Eve M. Segal · 2017 · Journal of the Advanced Practitioner in Oncology
  15. Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study
    Mahadev Rao, Rosella Ayesha Pinto, Arpita Roy, Levin Thomas, Karthik Udupa, Vasudeva Guddattu · 2022 · Current Drug Safety
  16. Approved and Clinical Trial Third-Generation EGFR Inhibitors
    Harun Patel, Rahul H. Pawara, Sanjay Javerilal Surana · 2019 · Elsevier eBooks
  17. Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
    Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Da‐Peng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou · 2021 · Pharmaceutical Biology
  18. A UHPLC–MS/MS method for the quantitation of olmutinib in rat plasma
    Su‐su Bao, Jian Ming Wen, Tenghui Liu, Bo-wen Zhang, Chenchen Wang, Guoxin Hu · 2018 · Acta Chromatographica
  19. Subtype of EGFR exon 19 deletion mutations
    Nobukazu Fujimoto · 2024 · Translational Lung Cancer Research
  20. Pharmacokinetics and Bioequivalence Evaluation of Erlotinib Hydrochloride Tablets: Randomized, Open‐Label, 2‐Period Crossover Study in Healthy Chinese Subjects
    Lu Wang, Zourong Ruan, Dandan Yang, Yin Hu, Jian Liang, Jinliang Chen, Rong Shao, Yichao Xu, Yanlu Guan, Bo Jiang · 2020 · Clinical Pharmacology in Drug Development
  21. The alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbits
    Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak · 2016 · Pharmacological Reports
  22. Effects of Bojungikkitang (a Polyherbal Formula), on Gefitinib Pharmacokinetics in Rats
    Dae-Sung Hyun, Jong-Dae Kim, Jun-Hyeong Park, Soo‐Jin Park, Chang-Hyun Song, Sae‐Kwang Ku · 2015 · International Journal of Pharmacology
  23. Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
    Yvonne Summers, Donna M. Graham · 2019 · European Journal of Oncology Pharmacy
  24. Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines
    Tharsagini V. Nanthaprakash, Campbell W. Gourlay, Ina Oehme, Michelle Dawn Garrett, Jindrich Cínatl, Mark N. Wass, Martin Michaelis · 2025 · FEBS Open Bio
  25. Tyrosine-kinase inhibitors for lung or breast cancer and drug–drug interactions: a clinical guide
    Fiorenza Santamaria, Michela Roberto, Giulia Maltese, Francesco Nicolella, Andrea Torchia, Dorelsa Buccilli, Mattia Alberto Di Civita, Paola Giancontieri, Daniele Marinelli, Alessio Cirillo et al. · 2025 · Oncology Reviews
  26. Core-shell nanofibers integrating growth factor-loaded nanoparticles for spatio-temporal delivery in chronic wound healing
    Ovidio Catanzano, Irene Bonadies, Clara Gamba, Michele Guida, Gennaro Roberto Abbamondi, Giuseppina Tommonaro, Hossam Ahmed, Fabiana Quaglia, Joshua S. Boateng · 2026 · Biomaterials Advances
  27. Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR–MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab
    Piotr Kawczak, Tomasz Bączek · 2026 · Journal of Clinical Medicine
  28. Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses
    Siqi Zhou, Guoxin Cai, Xue Meng, Mengying Li, Ying Fu, Xiaohan Wang, Kaiyue Wang, Han Xiao · 2024 · Clinical & Translational Oncology
  29. Exploration of novel quinoline derivatives: Anticancer potential revealed through design, synthesis and biological evaluation
    Janaiah Chevula, Saikrishna Balabadra, Ramakrishna Munnaluri, Vijjulatha Manga · 2025 · Journal of Chemical Sciences
  30. Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer
    Gagan Chhabra · 2015 · Archives in Cancer Research
  31. Effects of Angelica gigas extract on the oral pharmacokinetics of gefitinib in rats
    Hyerim Kim, Jong‐Woo Jeong, Sang Hoon Joo, Tae‐Sung Koo · 2017 · Journal of Pharmaceutical Investigation
  32. Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
    Ana Hečimović, Andrea Vukić Dugac, Mateja Janković Makek, Maja Čikeš, Miroslav Samaržija, Marko Jakopović · 2019 · Monaldi Archives for Chest Disease
  33. Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors
    Aygin Bayraktar‐Ekincioglu · 2018 · International Journal of Hematology and Oncology
  34. Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling
    Mohamed W. Attwa, Adnan A. Kadi, Haitham K. Alrabiah, Hany W. Darwish · 2019 · RSC Advances
  35. Tuberculosis in epidermal growth factor receptor mutation in lung adenocarcinoma on treatment with gefitinib/erlotinib
    Dipti Gothi, Sonam Spalgais · 2017 · Indian Journal of Cancer
  36. Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
    Mengli Wang, Qiuzheng Du, Lihua Zuo, Peng Xue, Chao Lan, Zhi Sun · 2020 · Current Drug Metabolism
  37. Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors
    Ting Yang, Xiaoling He, Ting Wu, Wenqiang Zhu, Zhiwu Long, Yi Le · 2024 · Molecular Diversity
  38. Precision, accuracy, and resolution—Dose selection of oral anticancer agents
    Tyler J. Beardslee, Robert Donald Harvey · 2016 · Cancer
  39. Identification of FDA-Approved Drugs as Modulators of Multidrug Resistance Protein 2 (MRP2/ABCC2) Expression Levels in MRP2-Overexpressing Cells: Preliminary Data
    Vivian Osei Poku, Surtaj Hussain Iram · 2024 · Journal of Biosciences and Medicines
  40. Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes
    Otto Manninen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen · 2025 · Oncology
  41. Potential Drug-Drug Interactions With Tyrosine Kinase Inhibitors
    Radeva-Ilieva Maya, Bogdan Kirilov, Kaloyan Georgiev · 2019 · Annual for Hospital Pharmacy
  42. Afatinib
    Giuseppe Tridente · 2017 · Elsevier eBooks
  43. Mitogen-Activated Protein Kinase Signaling and Cancer
    Mutsuhiro Takekawa, Yuji Kubota · 2015 · Springer eBooks
  44. Overview
    Giuseppe Tridente · 2017 · Elsevier eBooks
  45. A model of NSCLC microenvironment predicts optimal receptor targets
    Chuang Han, Yu Wu · 2019 · Quantitative Biology
  46. Tirosyne Kinase Inhibithors (TKIs) in the Treatment of Non –Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
    Alexandru Călin Grigorescu, Teodorescu Laura Mihaela · 2020 · Journal of Drug Delivery and Therapeutics
  47. Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report
    Shuang Bian, Xiaomiao Tang, Sheng Ye, Wei Lei · 2020 · Respiratory Medicine Case Reports
  48. Meme Kanseri Tedavisinde Sinyal Yolaklarının Kritik Rolü
    Zehra Okat · 2023 · Özgür Yayınları eBooks
  49. In silico and in vitro tudies for identification of novel egfr tyrosine kinase inhibitors
    Duangjai Todsaporn · 2021
  50. Revisão Sistemática de Estudos Observacionais sobre o uso de Erlotinibe e Gefitinibe no Tratamento do Câncer de Pulmão de Células Não Pequenas
    Annemeri Livinalli, Barbara Delano Cruz, Isabel Cristina Martins Emmerick, Isabela de Pinho Pestana, Juliana Rodrigues Machado Rúgolo, Letícia Barbosa Teixeira, Mariana Michel Barbosa, Mário Jorge Sobreira da Silva · 2024 · Revista Brasileira de Cancerologia
  51. Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Sung‐yoon Yang, Lien Thi Ngo, Soyoung Lee, Hwi‐yeol Yun, Tham Thi Bui, Dong-Hyeon Kim, Jung‐woo Chae, Sojung Park · 2025 · Pharmaceuticals
  52. Acidifying agents impact erlotinib and gefitinib pharmacokinetic parameters and elevate liver enzymes in Wistar rats
    Amsha S. Alsegiani, Aliyah A. Almomen, Maria Arafah, Nourah Z. Alzoman, Abdullah K. Alshememry · 2025 · Saudi Pharmaceutical Journal
  53. Chinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safety
    Xia Li, Die Qian, Shuai Liu, Mingmin Na, 戴碧鸿, Chunping Wan · 2026 · Frontiers in Oncology
  54. BindingDB Entry 50022681: FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.
    BindingDB · 2026 · UC San Diego
  55. BindingDB Entry 50003219: Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
    BindingDB · 2020 · UC San Diego
  56. BindingDB Entry 50009645: Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
    BindingDB · 2021 · UC San Diego
  57. BindingDB Entry 50013124: Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.
    BindingDB · 2022 · UC San Diego
  58. BindingDB Entry 50017048: Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
    BindingDB · 2023 · UC San Diego
  59. BindingDB Entry 50018884: Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
    BindingDB · 2024 · UC San Diego
  60. BindingDB Entry 50023144: Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers.
    BindingDB · 2026 · UC San Diego
  61. BindingDB Entry 50001303: Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    BindingDB · 2020 · UC San Diego
  62. BindingDB Entry 50013716: Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
    BindingDB · 2022 · UC San Diego
  63. BindingDB Entry 50012225: Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
    BindingDB · 2022 · UC San Diego